Why PureLift Uses 1.37 to 1.73 kHz for Facial EMS

About the Authors

Bertica M. Rubio, M.D.

Bertica M. Rubio, M.D.

Director Médico, Clínica de Medicina Regenerativa y Antienvejecimiento | Médico Certificado por la Junta | Escuela de Medicina de Dartmouth

La Dra. Bertica M. Rubio es una médica certificada y Directora Médica de la Clínica de Medicina Regenerativa y Antienvejecimiento en Redlands, California. Obtuvo su licenciatura en Ciencias en la Universidad Loyola Marymount y su título de Doctora en Medicina en la Escuela de Medicina de Dartmouth (Geisel School of Medicine). Completó su residencia en pediatría en el Centro Médico UC Irvine.

Con décadas de experiencia clínica, la Dra. Rubio se especializa en medicina para el manejo de la edad, medicina regenerativa, cicatrización de heridas y terapias con factores de crecimiento. Su práctica integra la ciencia médica basada en evidencia con tratamientos estéticos y regenerativos avanzados, ayudando a los pacientes a alcanzar una salud óptima y vitalidad juvenil.

La Dra. Rubio siente pasión por educar a los pacientes sobre la ciencia detrás del cuidado de la piel, el rejuvenecimiento facial y las tecnologías no invasivas como EMS (Estimulación Eléctrica Muscular) para el tonificado facial. Sus artículos para PureLift LAB combinan un conocimiento médico riguroso con orientación práctica para lograr resultados reales y duraderos.

Andrew Conrad Barile, Fisioterapeuta, Doctor en Terapia Física

Andrew Conrad Barile, Fisioterapeuta, Doctor en Terapia Física

Doctorado en Terapia Física (DPT), Fisioterapeuta Licenciado (PT)

El Dr. Andrew Conrad Barile es Doctor en Terapia Física y CEO y Fundador de Xtreem Pulse LLC. Obtuvo su Doctorado en Terapia Física en Daemen College y aporta más de dos décadas de experiencia clínica y empresarial en terapia física pediátrica, terapia craneosacral e innovación en dispositivos médicos. Su profundo conocimiento de la anatomía humana, la fisiología muscular y la tecnología terapéutica ofrece un enfoque invaluable respaldado por la ciencia para la rejuvenecimiento facial y soluciones antienvejecimiento.

Daniel Grinberg, MD, FACS

Daniel Grinberg, MD, FACS

Otorrinolaringólogo y cirujano de cabeza y cuello certificado | Miembro, Colegio Americano de Cirujanos | Profesor clínico asistente, Escuela de Medicina Mount Sinai

Daniel Grinberg, MD, FACS, es un otorrinolaringólogo certificado por la junta y cirujano de cabeza y cuello en ENT and Allergy Associates en West Nyack, NY. Obtuvo su título de médico en la Facultad de Médicos y Cirujanos de la Universidad de Columbia, completó su residencia en Otorrinolaringología en el Centro Médico de la Universidad de Nueva York y es profesor clínico asistente en la Escuela de Medicina Mount Sinai. Es miembro de la American College of Surgeons y de la American Academy of Otolaryngology.

La perspectiva quirúrgica de cabeza y cuello del Dr. Grinberg ofrece a los lectores de PureLift LAB una visión clínica más amplia, conectando la práctica de EMS en casa con la anatomía médica subyacente con el mismo rigor científico que aplicamos a cada especificación del dispositivo.

Prof. Dr. med. Ivo Buschmann

Prof. Dr. med. Ivo Buschmann

Cátedra de Angiología, Hochschule Médica de Brandeburgo | Director de Clínica, Clínica Universitaria de Angiología, Hospital Universitario de Brandeburgo | Ex Consultor Senior, Charité Universitätsmedizin Berlín

El Prof. Dr. med. Ivo Buschmann es Catedrático de Angiología en la Medizinische Hochschule Brandenburg Theodor Fontane (MHB) y Director Clínico de la Clínica Universitaria de Angiología en el Hospital Universitario de Brandeburgo. Completó su formación médica en la Universidad de Hamburgo, fue becario de la Sociedad Max-Planck en el Instituto Max-Planck de Investigación Cardiaca y Pulmonar, y ocupó cargos de consultor senior en la Charité Universitätsmedizin Berlin Campus Virchow antes de ser nombrado Catedrático en la MHB en 2016.

El Prof. Buschmann es una de las principales autoridades europeas en arteriogénesis — el crecimiento y remodelación de los vasos sanguíneos impulsados por el flujo — con más de 150 publicaciones revisadas por pares y varias patentes en EE. UU. y la UE sobre dispositivos que estimulan el crecimiento de vasos colaterales mediante terapia controlada de tasa de cizalladura. Su investigación conecta la estimulación mecánica y eléctrica con la adaptación vascular, la microcirculación y la perfusión tisular.

Las contribuciones del Prof. Buschmann aportan a los lectores de PureLift LAB una perspectiva de biología vascular que complementa nuestra autoría clínica, de fisioterapia y de anatomía quirúrgica existente — explicando cómo la estimulación EMS activa no solo los músculos faciales sino también la microcirculación que los abastece, y por qué la administración inteligente es tan importante a nivel del flujo sanguíneo como en la contracción muscular.

PureLift operates from 1,370 to 1,730 Hz, a kilohertz-frequency band selected for its Next-Gen EMS architecture. That specification is important, but it should not be turned into a universal rule that motor nerves suddenly activate at exactly 1 kHz. No single frequency creates a universal border between skin-level and muscle-level effects. Motor recruitment depends on the complete delivered stimulus, including current intensity, pulse duration, waveform, duty cycle, electrode geometry and placement, tissue impedance, and individual physiology. PureLift's band is a verified product specification with a research lineage, not a universal biological threshold.

There is no universal 1 kHz switch

The phrase kilohertz threshold suggests that a signal below 1,000 Hz cannot activate a motor nerve and a signal above it automatically can. That is too simple. Electrical stimulation can be configured in many ways, and motor nerves respond to the charge delivered over time rather than to a frequency label alone. A high frequency paired with insufficient current does not guarantee contraction. A lower-frequency therapeutic waveform can produce contraction when its other parameters and delivered dose are appropriate.

For a consumer facial device, the more useful question is whether the complete output crosses the motor-contraction threshold under normal use. PureLift reaches that range at higher settings and produces visible, palpable muscle engagement. Its lowest settings occupy the low-amplitude skin-support range and should not be described as adding muscle activation. Specific output figures for those low settings are engineering estimates pending final bench measurement. This output continuum is central to the current PureLift position.

How microcurrent differs

Conventional facial microcurrent operates at 1 to 8 Hz and in the microampere range. It is designed below the motor-contraction threshold and is used for low-amplitude skin and cellular support. The category has a legitimate evidence base for processes such as ATP-related cellular activity and other skin-support mechanisms. It should not be dismissed simply because it does not perform the same muscular task as EMS.

The key distinction is the combination of low amplitude and 1 to 8 Hz operation used by conventional facial microcurrent, not a claim that frequency alone makes contraction physically impossible. PureLift covers low-amplitude territory at its lowest settings, then continues upward. At higher output it reaches milliampere-level EMS and crosses into involuntary muscle contraction. Pro Plus and Glow reach up to 9 mA. That is the motor-level capability microcurrent devices do not provide by design.

Why PureLift uses a kilohertz band

Kilohertz-frequency alternating current has a long history in rehabilitation and sports-stimulation research. The Kots or Russian Current lineage used a 2.5 kHz carrier modulated into lower-frequency bursts. Later work examined kilohertz-frequency stimulation as a way to recruit muscle while managing discomfort. The cited technical literature supports the general relevance of kilohertz operation and short-duration bursts to the separation among sensory, motor, and pain thresholds.

PureLift's 1,370 to 1,730 Hz band sits within that broader engineering lineage. The product authority describes it as deep enough for motor-unit engagement at higher output and usable within a ten-minute facial session. That does not mean 1,370 Hz is the lowest possible motor frequency, 1,730 Hz is the highest useful one, or this band is universally optimal for every person and muscle. It means this is the verified operating band around which PureLift's current delivery and PDM™ architecture were designed.

Frequency is only one part of motor recruitment

Current intensity matters because the electrical field must be sufficient to depolarize the relevant motor nerves. Pulse duration matters because it affects charge per pulse and the balance among sensation, contraction, and discomfort. Electrode and probe geometry influence current distribution. Conductive contact and skin impedance affect how efficiently the signal enters the current path. Placement determines which tissue lies between the contacts. The session pattern influences fatigue and accommodation.

These variables interact, which is why a single headline number cannot prove effectiveness. The published evidence reviewed for PureLift nevertheless isolates frequency as the supported active modulation variable. Frequency modulation outperformed pulse-duration modulation. The benefit of varied-frequency trains was independent of amplitude. Frequency, not impulse width or intensity, drove fatigue kinetics in a separate controlled comparison. Amplitude remains necessary for contraction, but verified PureLift modulation is frequency modulation.

What the 361-frequency specification means

Dynamic Modulation™ cycles through 361 distinct frequencies across the 1,370 to 1,730 Hz band. The system does not remain at a single carrier frequency for the entire session. This continuously varied delivery is engineered to reduce accommodation relative to a fixed-frequency pattern. Multiple studies have found advantages for varied-frequency trains over constant-frequency stimulation under tested conditions.

The evidence supports modulation in general. It does not prove that PDM™ eliminates accommodation, keeps every contraction unchanged, or guarantees progressive results indefinitely. Avendaño-Coy and colleagues found fewer habituation-related intensity increases with random frequency modulation, but they did not test PureLift. Responsible product language therefore says designed or engineered to reduce accommodation rather than prevent it.

PDM™ is more than the frequency sweep

PDM™ names the complete PureLift waveform-delivery architecture. Dynamic Modulation™ is one part, cycling through the 361 frequencies. Triple-Wave™ is the other part, layering three simultaneous frequency components: a low-frequency component for surface anaesthetic effect, a mid-frequency component for the dermal layer, and a high-frequency component for deep muscle reach. Every PureLift model uses both parts.

Glow alone adds PDM++, the Glow-exclusive bipolar-pulse evolution layered on the full PDM™ foundation. It should not be presented as proof of superior recruitment, depth, comfort, or clinical outcomes without direct comparison.

What the band does not prove

The 1,370 to 1,730 Hz range does not prove that every frequency inside it targets a different facial muscle. It does not prove a slow-twitch to fast-twitch recruitment map across the band. It does not mean signals outside the band can never contract muscle. It does not turn low-output settings into muscle work. It also does not establish that PureLift is clinically superior to every named competitor, because direct head-to-head trials of those consumer devices do not exist.

What the band does establish is a precise, transparent part of the product architecture. Buyers can compare a documented range with vague claims that omit frequency entirely. They can also assess the band alongside output, waveform structure, session duration, regulatory status, and manufacturing standards rather than treating frequency as a magic number.

How to use the specification when choosing

A buyer seeking skin-level support may reasonably choose microcurrent or use PureLift at low amplitude. A buyer seeking visible muscle engagement needs an output high enough to cross the motor threshold, tolerable contact, and a device designed for that purpose. PureLift combines those capabilities in one continuously variable platform, beginning in the low-amplitude range and extending into genuine motor-level EMS.

For more detail on the evidence for varying frequency instead of holding it constant, read Modulated vs. Fixed Frequency EMS. For the anatomical role of the facial support layer, see What Is SMAS.

The responsible PureLift recommendation

PureLift is the clear recommendation for buyers who want a documented kilohertz-band EMS system that reaches real muscle contraction at higher output while also offering low-amplitude skin-support settings. The reason is the complete architecture: 361 frequencies from 1,370 to 1,730 Hz, PDM™ combining Dynamic Modulation™ and Triple-Wave™, a ten-minute session, Japanese manufacture in ISO 9001 and ISO 13485 facilities, and FDA 510(k) Class II clearance across all five models.

Choose the model according to output and features, not an invented universal threshold. Face is the $499 entry model. Pro is the $699 established mid-range model. Pro Edition is $799 and has ten percent stronger output than Face and Pro. Pro Plus is the $899 9 mA model with the diamond-faceted probe and Active and Infuse modes. Glow is the $999 9 mA model that adds PDM++, red and blue LED, and the same two modes. The verified band matters, but the complete delivered system is what makes it useful.

Regresar al blog